A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions
Prostate CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-sensitive Prostate Cancer
Interventions
DRUG

PRL-02 injection

abiraterone decanoate for intramuscular injection

DRUG

prednisone

Oral dose

DRUG

dexamethasone

Oral dose

DRUG

enzalutamide

Oral capsule

Trial Locations (24)

19004

RECRUITING

MidLantic Urology, Bala-Cynwyd

21204

RECRUITING

Chesapeake Urology, Towson

22908

RECRUITING

University of Virginia Cancer Center, Charlottesville

27710

RECRUITING

Duke Cancer Center, Durham

29572

RECRUITING

Carolina Urologic Research Center, Myrtle Beach

33609

RECRUITING

Florida Urology Partners, Tampa

37209

RECRUITING

Urology Associates PC, Nashville

43623

WITHDRAWN

Toledo Clinical Cancer Center, Toledo

44130

WITHDRAWN

Helios Clinical Research, LLC, Middleburg Heights

46804

RECRUITING

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

47130

RECRUITING

First Urology, Jeffersonville

67226

RECRUITING

Wichita Urology Group, Wichita

68130

COMPLETED

XCancer Center Omaha/Urology Cancer Center, Omaha

75231

RECRUITING

Urology Clinics of North Texas, Dallas

77027

RECRUITING

Houston Metro Urology, Houston

77030

RECRUITING

Oncology Consultants, Houston

78229

WITHDRAWN

Urology San Antonio, San Antonio

85715

RECRUITING

Arizona Urology Specialists, Tucson

87109

RECRUITING

New Mexico Oncology Hematology Consultants Ltd, Albuquerque

92801

RECRUITING

Los Angeles Cancer Network, Anaheim

95403

RECRUITING

Providence Medical Group Oncology Santa Rosa, Santa Rosa

98405

RECRUITING

Northwest Medical Specialties, Tacoma

07960

RECRUITING

Garden Sate Urology, Morristown

00935

RECRUITING

Pan American Center for Oncology Trials, LLC, San Juan

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY